References

1. Prager, G.W.; Braga, S.; Bystricky, B.; Qvortrup, C.; Criscitiello, C.; Esin, E.; Sonke, G.S.; Martínez, G.A.; Frenel, J.-S.; Karamouzis, M.; et al. Global cancer control: Responding to the growing burden, rising costs and inequalities in access. ESMO Open 2018, 3, e000285.Gerald W. Prager; Sofia Braga; Branislav Bystricky; Camilla Qvortrup; Carmen Criscitiello; Ece Esin; Gabe S. Sonke; Guillem Argilés Martínez; Jean-Sebastian Frenel; Michalis Karamouzis; et al.Michiel StrijbosOzan YaziciPaolo BossiSusana BanerjeeTeresa TroianiAlexandru EniuFortunato CiardielloJosep TaberneroChristoph C. ZielinskiPaolo G. CasaliFatima CardosoJean-Yves DouillardSvetlana JezdicKeith McGregorGracemarie BricalliMalvika VyasAndré Ilbawi Global cancer control: responding to the growing burden, rising costs and inequalities in access. ESMO Open 2018, 3, e000285, 10.1136/esmoopen-2017-000285.
2. Ferlay, J.; Soerjomataram, I.; Dikshit, R.; Eser, S.; Mathers, C.; Rebelo, M.; Parkin, D.M.; Forman, D.; Bray, F. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 2014, 136, E359–E386.
3. Rizza, P.; Pellegrino, M.; Caruso, A.; Iacopetta, D.; Sinicropi, M.S.; Rault, S.; Lancelot, J.C.; El-Kashef, H.; Lesnard, A.; Rochais, C.; et al. 3-(Dipropylamino)-5-hydroxybenzofuro[2,3-f]quinazolin-1(2H)-one (DPA-HBFQ-1) plays an inhibitory role on breast cancer cell growth and progression. Eur. J. Med. Chem. 2016, 107, 275–287.
4. Nagajyothi, P.; Muthuraman, P.; Sreekanth, T.; Kim, D.H.; Shim, J. Green synthesis: In-vitro anticancer activity of copper oxide nanoparticles against human cervical carcinoma cells. Arab. J. Chem. 2017, 10, 215–225.
5. Husinka, L.; Koerner, P.H.; Miller, R.T.; Trombatt, W. Review of cyclin-dependent kinase 4/6 inhibitors in the treatment of advanced or metastatic breast cancer. J. Drug Assess. 2021, 10, 27–34.
6. Spring, L.M.; Wander, S.A.; Zangardi, M.; Bardia, A. CDK 4/6 Inhibitors in Breast Cancer: Current Controversies and Future Directions. Curr. Oncol. Rep. 2019, 21, 1–9.
7. Marra, A.; Curigliano, G. Are all cyclin-dependent kinases 4/6 inhibitors created equal? NPJ Breast Cancer 2019, 5, 1–9.
8. Miller, T.W.; Balko, J.M.; Fox, E.M.; Ghazoui, Z.; Dunbier, A.; Anderson, H.; Dowsett, M.; Jiang, A.; Smith, R.A.; Maira, S.-M.; et al. ERα-Dependent E2F Transcription Can Mediate Resistance to Estrogen Deprivation in Human Breast Cancer. Cancer Discov. 2011, 1, 338–351.
9. Im, S.-A.; Lu, Y.-S.; Bardia, A.; Harbeck, N.; Colleoni, M.; Franke, F.; Chow, L.; Sohn, J.; Lee, K.-S.; Campos-Gomez, S.; et al. Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. N. Engl. J. Med. 2019, 381, 307–316.
10. Finn, R.S.; Martin, M.; Rugo, H.S.; Jones, S.E.; Im, S.-A.; Gelmon, K.A.; Harbeck, N.; Lipatov, O.N.; Walshe, J.M.; Moulder, S.L.; et al. PALOMA-2: Primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/HER2– advanced breast cancer (ABC). J. Clin. Oncol. 2016, 34, 507.
11. Verma, S.; Bartlett, C.H.; Schnell, P.; DeMichele, A.M.; Loi, S.; Ro, J.; Colleoni, M.; Iwata, H.; Harbeck, N.; Cristofanilli, M.; et al. Palbociclib in Combination with Fulvestrant in Women with Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3). Oncologist 2016, 21, 1165–1175.
12. Paranjpe, R.; John, G.; Trivedi, M.; Abughosh, S. Identifying adherence barriers to oral endocrine therapy among breast cancer survivors. Breast Cancer Res. Treat. 2018, 174, 297–305.
13. Cafeo, G.; Carbotti, G.; Cuzzola, A.; Fabbi, M.; Ferrini, S.; Kohnke, F.H.; Papanikolaou, G.; Plutino, M.R.; Rosano, C.; White, A.J.P. Drug Delivery with a Calixpyrrole–trans-Pt(II) Complex. J. Am. Chem. Soc. 2013, 135, 2544–2551.
14. Saturnino, C.; Napoli, M.; Paolucci, G.; Bortoluzzi, M.; Popolo, A.; Pinto, A.; Longo, P. Synthesis and cytotoxic activities of group 3 metal complexes having monoanionic tridentate ligands. Eur. J. Med. Chem. 2010, 45, 4169–4174.
15. Romeo, R.; Scolaro, L.M.; Plutino, M.R.; Albinati, A. Structural properties of the metallointercalator cationic complex (2,2′:6′,2″-terpyridine)methylplatinum(II) ion. J. Organomet. Chem. 2000, 593, 403–408.
16. Malik, P.; Mukherjee, T.K. Recent advances in gold and silver nanoparticle based therapies for lung and breast cancers. Int. J. Pharm. 2018, 553, 483–509.
17. Langer, C.J.; Gadgeel, S.M.; Borghaei, H.; Papadimitrakopoulou, V.A.; Patnaik, A.; Powell, S.F.; Gentzler, R.D.; Martins, R.G.; Stevenson, J.P.; I Jalal, S.; et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: A randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 2016, 17, 1497–1508.
18. Cohen, H.; Levy, R.J.; Gao, J.; Fishbein, I.; Kousaev, V.; Sosnowski, S.; Slomkowski, S.; Golomb, G. Sustained delivery and expression of DNA encapsulated in polymeric nanoparticles. Gene Ther. 2000, 7, 1896–1905.
19. Gref, R.; Minamitake, Y.; Peracchia, M.T.; Trubetskoy, V.; Torchilin, V.; Langer, R.; Kamb, A.; Gruis, N.; Weaver-Feldhaus, J.; Liu, Q.; et al. Biodegradable long-circulating polymeric nanospheres. Science 1994, 263, 1600–1603.
20. Zanella, A.; Gandin, V.; Porchia, M.; Refosco, F.; Tisato, F.; Sorrentino, F.; Scutari, G.; Rigobello, M.P.; Marzano, C. Cytotoxicity in human cancer cells and mitochondrial dysfunction induced by a series of new copper(I) complexes containing tris(2-cyanoethyl)phosphines. Investig. New Drugs 2010, 29, 1213–1223.
21. Dhanyalayam, D.; Scrivano, L.; Parisi, O.I.; Sinicropi, M.S.; Fazio, A.; Saturnino, C.; Plutino, M.R.; Di Cristo, F.; Puoci, F.; Cappello, A.R.; et al. Biopolymeric self-assembled nanoparticles for enhanced antibacterial activity of Ag-based compounds. Int. J. Pharm. 2017, 517, 395–402.
22. Tiekink, E.R. Gold derivatives for the treatment of cancer. Crit. Rev. Oncol. 2002, 42, 225–248.
23. Kumar, A.; Boruah, B.M.; Liang, X.-J. Gold Complexes as Prospective Metal-Based Anticancer Drugs. Encycl. Met. 2013, 23, 867–875.
24. Kudgus, R.A.; Bhattacharya, R.; Mukherjee, P. Cancer nanotechnology: Emerging role of gold nanoconjugates. Anti-Cancer Agents Med. Chem. 2011, 11, 965–973.
25. Maeda, H.; Wu, J.; Sawa, T.; Matsumura, Y.; Hori, K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review. J. Control. Release 2000, 65, 271–284.
26. Brigger, I.; Dubernet, C.; Couvreur, P. Nanoparticles in cancer therapy and diagnosis. Adv. Drug Deliv. Rev. 2012, 64, 24–36.
27. Fenart, L.; Casanova, A.; Dehouck, B.; Duhem, C.; Slupek, S.; Cecchelli, R.; Betbeder, D. Evaluation of effect of charge and lipid coating on ability of 60-nm nanoparticles to cross an in vitro model of the blood-brain barrier. J. Pharmacol. Exp. Ther. 1999, 291, 1017–1022.
28. Huynh, N.; Passirani, C.; Saulnier, P.; Benoit, J. Lipid nanocapsules: A new platform for nanomedicine. Int. J. Pharm. 2009, 379, 201–209.
29. Maeda, H. Tumor-Selective Delivery of Macromolecular Drugs via the EPR Effect: Background and Future Prospects. Bioconjugate Chem. 2010, 21, 797–802.
30. Cho, K.; Wang, X.; Nie, S.; Chen, Z.; Shin, D.M. Therapeutic Nanoparticles for Drug Delivery in Cancer. Clin. Cancer Res. 2008, 14, 1310–1316.
31. Iacopetta, D.; Grande, F.; Caruso, A.; Mordocco, R.A.; Plutino, M.R.; Scrivano, L.; Ceramella, J.; Muià, N.; Saturnino, C.; Puoci, F.; et al. New insights for the use of quercetin analogs in cancer treatment. Future Med. Chem. 2017, 9, 2011–2028.
32. Misra, R.; Acharya, S.; Sahoo, S.K. Cancer nanotechnology: Application of nanotechnology in cancer therapy. Drug Discov. Today 2010, 15, 842–850.
33. Murphy, C.J.; Gole, A.M.; Stone, J.W.; Sisco, P.N.; Alkilany, A.M.; Goldsmith, E.C.; Baxter, S.C. Gold Nanoparticles in Biology: Beyond Toxicity to Cellular Imaging. Accounts Chem. Res. 2008, 41, 1721–1730.
34. Bhattacharya, R.; Mukherjee, P.; Xiong, Z.; Atala, A.; Soker, A.S.; Mukhopadhyay, D. Gold Nanoparticles Inhibit VEGF165-Induced Proliferation of HUVEC Cells. Nano Lett. 2004, 4, 2479–2481.
35. Daniel, M.-C.; Astruc, D. Gold Nanoparticles: Assembly, Supramolecular Chemistry, Quantum-Size-Related Properties, and Applications toward Biology, Catalysis, and Nanotechnology. Chem. Rev. 2004, 104, 293–346.
36. Brust, M.; Kiely, C.J. Some recent advances in nanostructure preparation from gold and silver particles: A short topical review. Colloids Surf. A Physicochem. Eng. Asp. 2002, 202, 175–186.
37. McConnell, W.P.; Novak, J.P.; Brousseau, L.C.; Fuierer, R.R.; Tenent, R.C.; Feldheim, D.L. Electronic and Optical Properties of Chemically Modified Metal Nanoparticles and Molecularly Bridged Nanoparticle Arrays. J. Phys. Chem. B 2000, 104, 8925–8930.
38. Chen, W.; Bardhan, R.; Bartels, M.; Perez-Torres, C.; Pautler, R.G.; Halas, N.J.; Joshi, A. A Molecularly Targeted Theranostic Probe for Ovarian Cancer. Mol. Cancer Ther. 2010, 9, 1028–1038.
39. Bardhan, R.; Chen, W.; Bartels, M.; Perez-Torres, C.; Botero, M.F.; McAninch, R.W.; Contreras, A.; Schiff, R.; Pautler, R.G.; Halas, N.J.; et al. Tracking of Multimodal Therapeutic Nanocomplexes Targeting Breast Cancer in Vivo. Nano Lett. 2010, 10, 4920–4928.
40. Quinn, J.F.; Raman, R.; Thomas, R.G.; Yurko-Mauro, K.; Nelson, E.B.; Van Dyck, C.; Galvin, J.E.; Emond, J.; Jack, C.R.; Weiner, M.; et al. Docosahexaenoic Acid Supplementation and Cognitive Decline in Alzheimer Disease. JAMA 2010, 304, 1903–1911.
41. Lu, W.; Arumugam, S.R.; Senapati, D.; Singh, A.K.; Arbneshi, T.; Khan, S.A.; Yu, H.; Ray, P.C.; Yu, S.A.K.H. Multifunctional Oval-Shaped Gold-Nanoparticle-Based Selective Detection of Breast Cancer Cells Using Simple Colorimetric and Highly Sensitive Two-Photon Scattering Assay. ACS Nano 2010, 4, 1739–1749.
42. Choi, M.-R.; Stanton-Maxey, K.J.; Stanley, J.K.; Levin, C.S.; Bardhan, R.; Akin, D.; Badve, S.; Sturgis, J.; Robinson, J.P.; Bashir, R.; et al. A Cellular Trojan Horse for Delivery of Therapeutic Nanoparticles into Tumors. Nano Lett. 2007, 7, 3759–3765.
43. Kim, D.; Jeong, Y.Y.; Jon, S. A Drug-Loaded Aptamer–Gold Nanoparticle Bioconjugate for Combined CT Imaging and Therapy of Prostate Cancer. ACS Nano 2010, 4, 3689–3696.
44. Patra, C.R.; Bhattacharya, R.; Wang, E.; Katarya, A.; Lau, J.S.; Dutta, S.; Muders, M.H.; Wang, S.; Buhrow, S.A.; Safgren, S.L.; et al. Targeted Delivery of Gemcitabine to Pancreatic Adenocarcinoma Using Cetuximab as a Targeting Agent. Cancer Res. 2008, 68, 1970–1978.
45. El-Sayed, I.H.; Huang, X.; El-Sayed, M.A. Selective laser photo-thermal therapy of epithelial carcinoma using anti-EGFR antibody conjugated gold nanoparticles. Cancer Lett. 2006, 239, 129–135.
46. Patra, C.R.; Bhattacharya, R.; Mukherjee, P. Fabrication and functional characterization of goldnanoconjugates for potential application in ovarian cancer. J. Mater. Chem. 2009, 20, 547–554.
47. De Luca, G.; Bonaccorsi, P.; Trovato, V.; Mancuso, A.; Papalia, T.; Pistone, A.; Casaletto, M.P.; Mezzi, A.; Brunetti, B.; Minuti, L.; et al. Tripodal tris-disulfides as capping agents for a controlled mixed functionalization of gold nanoparticles. New J. Chem. 2018, 42, 16436–16440.
48. Priya, M.R.K.; Iyer, P.R. Antiproliferative effects on tumor cells of the synthesized gold nanoparticles against Hep2 liver cancer cell line. Egypt. Liver J. 2020, 10, 1–12.
49. Bardhan, R.; Chen, W.; Perez-Torres, C.; Bartels, M.; Huschka, R.M.; Zhao, L.L.; Morosan, E.; Pautler, R.G.; Joshi, A.; Halas, N.J. Nanoshells with Targeted Simultaneous Enhancement of Magnetic and Optical Imaging and Photothermal Therapeutic Response. Adv. Funct. Mater. 2009, 19, 3901–3909.
50. Akiyama, Y.; Mori, T.; Katayama, Y.; Niidome, T. The effects of PEG grafting level and injection dose on gold nanorod biodistribution in the tumor-bearing mice. J. Control. Release 2009, 139, 81–84.
51. Mammen, M.; Choi, S.K.; Whitesides, G.M. Polyvalent interactions in biological systems: Implications for design and use of multivalent ligands and inhibitors. Angew. Chem. 1998, 37, 2754–2794.
52. Sinicropi, M.S.; Iacopetta, D.; Rosano, C.; Randino, R.; Caruso, A.; Saturnino, C.; Muià, N.; Ceramella, J.; Puoci, F.; Rodriquez, M.; et al. N-thioalkylcarbazoles derivatives as new anti-proliferative agents: Synthesis, characterisation and molecular mechanism evaluation. J. Enzym. Inhib. Med. Chem. 2018, 33, 434–444.
53. Iacopetta, D.; Rosano, C.; Puoci, F.; Parisi, O.I.; Saturnino, C.; Caruso, A.; Longo, P.; Ceramella, J.; Malzert-Fréon, A.; Dallemagne, P.; et al. Multifaceted properties of 1,4-dimethylcarbazoles: Focus on trimethoxybenzamide and trimethoxyphenylurea derivatives as novel human topoisomerase II inhibitors. Eur. J. Pharm. Sci. 2017, 96, 263–272.
54. Caruso, A.; Voisin-Chiret, A.S.; Lancelot, J.-C.; Sinicropi, M.S.; Garofalo, A.; Raulta, S. Novel and Efficient Synthesis of 5,8-dimethyl-9hcarbazol- 3-ol via a hydroxydeboronation reaction. Molecules 2007, 71, 2203–2210.
55. Sinicropi, M.S.; Lappano, R.; Caruso, A.; Santolla, M.F.; Pisano, A.; Rosano, C.; Capasso, A.; Panno, A.; Lancelot, J.C.; Rault, S.; et al. (6-Bromo-1,4-dimethyl-9H-carbazol-3-yl-methylene)-hydrazine (Carbhydraz) Acts as a GPER Agonist in Breast Cancer Cells. Curr. Top. Med. Chem. 2015, 15, 1035–1042.
56. Saturnino, C.; Caruso, A.; Longo, P.; Capasso, A.; Pingitore, A.; Caroleo, M.; Cione, E.; Perri, M.; Nicolo, F.; Nardo, V.; et al. Crystallographic Study and Biological Evaluation of 1,4-dimethyl-N-alkylcarbazoles†. Curr. Top. Med. Chem. 2015, 15, 973–979.
57. Saturnino, C.; Sinicropi, M.S.; Iacopettab, D.; Ceramella, J.; Caruso, A.; Muià, N.; Longo, P.; Rosace, G.; Galletta, M.; Ielo, I.; et al. N-Thiocarbazole-based gold nanoparticles: Synthesis, characterization and anti-proliferative activity evaluation. IOP Conf. Ser. Mater. Sci. Eng. 2018, 459, 012023.
58. Mook-Jung, I.; Han, S.-H.; Chang, Y.J.; Jung, E.S.; Kim, J.-W.; Na, D.L. Effective screen for amyloid β aggregation inhibitor using amyloid β-conjugated gold nanoparticles. Int. J. Nanomed. 2010, 6, 1–12.
59. Ceramella, J.; Mariconda, A.; Iacopetta, D.; Saturnino, C.; Barbarossa, A.; Caruso, A.; Rosano, C.; Sinicropi, M.S.; Longo, P. From coins to cancer therapy: Gold, silver and copper complexes targeting human topoisomerases. Bioorganic Med. Chem. Lett. 2020, 30, 126905.
60. Kilpin, K.J.; Dyson, P.J. Enzyme inhibition by metal complexes: Concepts, strategies and applications. Chem. Sci. 2013, 4, 1410–1419.
61. Chen, Z.-F.; Shi, Y.-F.; Liu, Y.-C.; Hong, X.; Geng, B.; Peng, Y.; Liang, H. TCM Active Ingredient Oxoglaucine Metal Complexes: Crystal Structure, Cytotoxicity, and Interaction with DNA. Inorg. Chem. 2012, 51, 1998–2009.
62. Saturnino, C.; Popolo, A.; Ramunno, A.; Adesso, S.; Pecoraro, M.; Plutino, M.R.; Rizzato, S.; Albinati, A.; Marzocco, S.; Sala, M.; et al. Anti-Inflammatory, Antioxidant and Crystallographic Studies of N-Palmitoyl-ethanol Amine (PEA) Derivatives. Molecules 2017, 22, 616.
63. Wilson, C.R.; Fagenson, A.M.; Ruangpradit, W.; Muller, M.T.; Munro, O.Q. Gold(III) Complexes of Pyridyl- and Isoquinolylamido Ligands: Structural, Spectroscopic, and Biological Studies of a New Class of Dual Topoisomerase I and II Inhibitors. Inorg. Chem. 2013, 52, 7889–7906.
64. Chimento, A.; Saturnino, C.; Iacopetta, D.; Mazzotta, R.; Caruso, A.; Plutino, M.R.; Mariconda, A.; Ramunno, A.; Sinicropi, M.S.; Pezzi, V.; et al. Inhibition of human topoisomerase I and II and anti-proliferative effects on MCF-7 cells by new titanocene complexes. Bioorganic Med. Chem. 2015, 23, 7302–7312.
65. Sâmia, L.B.P.; Parrilha, G.L.; Da Silva, J.G.; Ramos, J.P.; Souza-Fagundes, E.M.; Castelli, S.; Vutey, V.; Desideri, A.; Beraldo, H. Metal complexes of 3-(4-bromophenyl)-1-pyridin-2-ylprop-2-en-1-one thiosemicarbazone: Cytotoxic activity and investigation on the mode of action of the gold(III) complex. BioMetals 2016, 29, 515–526.
66. Saturnino, C.; Barone, I.; Iacopetta, D.; Mariconda, A.; Sinicropi, M.S.; Rosano, C.; Campana, A.; Catalano, S.; Longo, P.; Andò, S. N-heterocyclic carbene complexes of silver and gold as novel tools against breast cancer progression. Future Med. Chem. 2016, 8, 2213–2229.
67. Napoli, M.; Saturnino, C.; Sirignano, E.; Popolo, A.; Pinto, A.; Longo, P. Synthesis, characterization and cytotoxicity studies of methoxy alkyl substituted metallocenes. Eur. J. Med. Chem. 2011, 46, 122–128.
68. Caporale, A.; Palma, G.; Mariconda, A.; Del Vecchio, V.; Iacopetta, D.; Parisi, O.I.; Sinicropi, M.S.; Puoci, F.; Arra, C.; Longo, P.; et al. Synthesis and Antitumor Activity of New Group 3 Metallocene Complexes. Molecules 2017, 22, 526.
69. Sirignano, E.; Saturnino, C.; Botta, A.; Sinicropi, M.S.; Caruso, A.; Pisano, A.; Lappano, R.; Maggiolini, M.; Longo, P. Synthesis, characterization and cytotoxic activity on breast cancer cells of new half-titanocene derivatives. Bioorganic Med. Chem. Lett. 2013, 23, 3458–3462.
70. Saturnino, C.; Sirignano, E.; Botta, A.; Sinicropi, M.S.; Caruso, A.; Pisano, A.; Lappano, R.; Maggiolini, M.; Longo, P. New titanocene derivatives with high antiproliferative activity against breast cancer cells. Bioorganic Med. Chem. Lett. 2014, 24, 136–140.
71. Iacopetta, D.; Mariconda, A.; Saturnino, C.; Caruso, A.; Palma, G.; Ceramella, J.; Muià, N.; Perri, M.; Sinicropi, M.S.; Caroleo, M.C.; et al. Novel Gold and Silver Carbene Complexes Exert Antitumor Effects Triggering the Reactive Oxygen Species Dependent Intrinsic Apoptotic Pathway. ChemMedChem 2017, 12, 2054–2065.
72. Iacopetta, D.; Rosano, C.; Sirignano, M.; Mariconda, A.; Ceramella, J.; Ponassi, M.; Saturnino, C.; Sinicropi, M.S.; Longo, P. Is the Way to Fight Cancer Paved with Gold? Metal-Based Carbene Complexes with Multiple and Fascinating Biological Features. Pharmaceuticals 2020, 13, 91.
73. Talib, J.; Beck, J.L.; Ralph, S.F. A mass spectrometric investigation of the binding of gold antiarthritic agents and the metabolite [Au(CN)2]- to human serum albumin. JBIC J. Biol. Inorg. Chem. 2006, 11, 559–570.
74. Özdemir, I.; Denizci, A.; Ozturk, H.T.; Çetinkaya, B. Synthetic and antimicrobial studies on new gold(I) complexes of imidazolidin-2-ylidenes. Appl. Organomet. Chem. 2004, 18, 318–322.
75. Yan, J.J.; Chow, A.L.-F.; Leung, C.-H.; Sun, R.W.-Y.; Ma, D.-L.; Che, C.-M. Cyclometalated gold(iii) complexes with N-heterocyclic carbene ligands as topoisomerase I poisons. Chem. Commun. 2010, 46, 3893–3895.
76. Champness, N.R. The future of metal-organic frameworks. Dalton Trans. 2011, 40, 10311–10315.
77. Ward, J.R. Role of disease-modifying antirheumatic drugs versus cytotoxic agents in the therapy of rheumatoid arthritis. Am. J. Med. 1988, 85, 39–44.
78. Fries, J.F.; Bloch, D.; Spitz, P.; Mitchell, D.M. Cancer in rheumatoid arthritis: A prospective long-term study of mortality. Am. J. Med. 1985, 78, 56–59.
79. Simon, T.M.; Kunishima, D.H.; Vibert, G.J.; Lorber, A. Inhibitory effects of a new oral gold compound on hela cells. Cancer 1979, 44, 1965–1975.
80. Simon, T.M.; Kunishima, D.H.; Vibert, G.J.; Lorber, A. Screening trial with the coordinated gold compound auranofin using mouse lymphocyte leukemia P388. Cancer Res. 1981, 41, 94–97.
81. Mirabelli, C.K.; Jensen, B.D.; Mattern, M.R.; Sung, C.M.; Mong, S.M.; Hill, D.T.; Dean, S.W.; Schein, P.S.; Johnson, R.K.; Crooke, S.T. Cellular pharmacology of mu-[1,2-bis(diphenylphosphino)ethane]bis[(1-thio-beta-D-gluco pyranosato-S)gold(I)]: A novel antitumor agent. Anti-Cancer Drug Des. 1986, 1, 223–234.